2022
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
Nardone A, Qiu X, Spisak S, Nagy Z, Feiglin A, Feit A, Cohen Feit G, Xie Y, Font-Tello A, Guarducci C, Hermida-Prado F, Syamala S, Lim K, Munoz Gomez M, Pun M, Cornwell M, Liu W, Ors A, Mohammed H, Cejas P, Brock JB, Freedman ML, Winer EP, Fu X, Schiff R, Long HW, Metzger Filho O, Jeselsohn R. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Research 2022, 82: 3673-3686. PMID: 35950920, PMCID: PMC9588703, DOI: 10.1158/0008-5472.can-21-3186.Peer-Reviewed Original ResearchConceptsInvasive lobular breast cancerInvasive ductal cancerLobular breast cancerTamoxifen resistanceBreast cancerInferior long-term outcomesTumor progressionLong-term outcomesBreast cancer subtypesPotential therapeutic avenuesDuctal cancerClinical findingsPoor outcomeReceptor axisClinical trialsDisease progressionPatient outcomesPreclinical modelsClinical investigationRelated commentaryTherapeutic avenuesCancer subtypesTherapeutic resistanceCancerClinical samples
2008
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-Negative Breast Cancer: Risk Factors to Potential Targets. Clinical Cancer Research 2008, 14: 8010-8018. PMID: 19088017, DOI: 10.1158/1078-0432.ccr-08-1208.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBreast cancerRisk factorsTherapeutic approachesBasal-like breast cancerConventional cytotoxic therapyBasal-like subtypeNovel therapeutic targetClinical research programCytotoxic therapyClinical behaviorConventional agentsTherapeutic targetDistinct subtypesCancerImportant subgroupSubtypesPotential targetUnique subgroupClinical samplesMolecular biology platformsSubgroupsMolecular biologyDistinct outcomesFocus article